Guardant Health (NASDAQ:GH) had its price target raised by analysts at BTIG Research from $100.00 to $140.00. They now have a "buy" rating on the stock.
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S. [Yahoo! Finance]
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy